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Pulmonary hypertension (PH) is a potentially fatal complication of hematopoietic stem cell transplantation
(HSCT). Given its nonspeciﬁc clinical presentation, it is likely that this clinical entity is underdiagnosed after
HSCT. Data describing the incidence, risk factors, and etiology of PH in HSCT recipients are minimal. Physi-
cians caring for HSCT recipients should be aware of this severe post-transplant complication because timely
diagnosis and treatment may allow improved clinical outcomes. We summarize the pathophysiology, clinical
presentation, diagnosis, and management of PH in HSCT recipients.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION
Pulmonary hypertension (PH) is an uncommon and po-
tentially fatal condition associated with increased pulmo-
nary vascular resistance and elevated right ventricular
pressure. Elevated pulmonary arterial pressures can lead to
permanent changes in the pulmonary vasculature, right
ventricular failure, and death. The incidence of PH in
hematopoietic stem cell transplantation (HSCT) recipients is
unknown. The initial symptoms of PH are nonspeciﬁc, and
diagnosis can be challenging in this complex population. The
most commonly reported types of PH in HSCT recipients
are pulmonary arterial hypertension (PAH) and pulmonary
veno-occlusive disease (PVOD), depending on the location of
vascular injury. There are no uniform clinical management
strategies given the paucity of data describing PH in HSCT
recipients. In this review, we summarize the pathophysi-
ology, clinical presentation, available diagnostic tools, and
clinical interventions for HSCT recipients with PH.
PH AND HSCT
The ﬁrst account of PH as a complication of HSCT was
published in 1984 by Troussard et al. [1], who reported
autopsy ﬁndings consistent with PH in a 12-year-old boy
who underwent HSCT for acute lymphoblastic leukemia.
Including the report from Troussard et al., PH in HSCT
recipients has been described in 40 patients and reported in
16 single patient case reports and 7 case series of 2 to
8 patients [1-23]. This paucity of data provides little insight
into the etiology, incidence, and risk factors for PH after HSCTedgments on page 1554.
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opment of screening strategies and treatment approaches.
In reported cases, 55% of patients had underlying diag-
nosis of malignancy, 15% immunodeﬁciencies, and 30% ge-
netic disorders or marrow failure syndromes. PH is described
as occurring after myeloablative regimens (73%) as well as
reduced-intensity regimens. PH has been reported in both
children and adults, with a median age at transplant of
12.6 years (range, 1 month to 51 years), although most
reports describe children [1-23]. This may indicate reporting
bias, because PH is very infrequent in children, perhaps
making authors more likely to report the ﬁnding.
All patients who developed PH presented with new-
onset respiratory symptoms such as tachypnea, hypoxia,
and respiratory distress, and these symptoms occurred
a median of 70 days after transplant (range, 0 to 365). In the
40 patients reported in the literature, overall mortality was
55% (22 of 40), with 86% (19/22) of deaths attributed to PH
and 14% (3 of 22) to relapse of the primary malignancy
[1-23]. Patients had variable pulmonary vasculature
involvement. Most patients (28 of 40, 70%) were diagnosed
with PAH involving the pulmonary arterioles only, with
documented pulmonary arteriolar injury on the tissue
specimens and/or increased arterial vascular resistance
measured by cardiac catheterization [3,7,10,11,13,14,17,18,21-23].
Nine patients (23%) were reported to have PVOD, with
pulmonary venule involvement and vascular congestion
only [1,2,4,5,8,12,16,19,20]. Two patients (5%) were diag-
nosed as having mixed arteriolar-venous pathology, and,
ﬁnally, 1 patient had no documentation of the vascular
component involved [2,6].
Underlying endothelial injury can clearly occur both on the
pre- and postpulmonary capillary vasculature. However,
further investigation is required to understand themechanism
of endothelial damage. Patients received a variety of therapies
for PH, including steroids, anticoagulants, prostacyclines,Transplantation.
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5 inhibitors (sildenaﬁl), limiting any conclusions about the
effectiveness of clinical interventions [1-23]. Data indicate that
both pediatric and adult patients undergoing HSCT are at risk
ofdevelopingPH, andPHshouldbeconsidered inpatientswho
develop cardiorespiratory symptoms after transplantation.
Seven case series describing PH after HSCT are summa-
rized in Table 1. The exact incidence of PH in HSCT population
remains unknown due to a lack of prospective studies;
however, the prevalence of PH was reported in a few retro-
spective reports. Schechter et al. [23] performed a retro-
spective analysis of all pediatric patients who underwent
serial autologous transplantation for central nervous system
tumors between 2001 and 2010. They found PH in 3 of 20
patients (15%), with 2 dying from progressive respiratory
disease. Steward et al. [11] described PH occurring in 8 of 29
pediatric patients (28%) with malignant infantile osteopet-
rosis over a 6-year period of time, suggesting a possible
particular susceptibility in children with that diagnosis. Five
of the 8 children (62%) with osteopetrosis died from respi-
ratory disease. In a recent pediatric series, Jodele et al. [22]
reported a prevalence of PH of 2.4% (5 of 209), with 80%
PH-associated mortality. In this report, all patients who
developed PH were also diagnosed with transplant-
associated thrombotic microangiopathy (TA-TMA), suggest-
ing that endothelial damage due to TA-TMA may play a role
in the pathogenesis of PH.
Pulmonary complications after HSCT are common and
caused by various etiologies, so PH can be overlooked [24].
PH should be considered in patients who develop respiratory
symptoms after HSCT. Prospective studies are needed to
determine the incidence of PH as well as associated risk
factors and to allow for targeted screening of high-risk cases.
Further research to determine the underlying cause and
mechanism of endothelial injury in PH will help identify
future therapies and prevention strategies.
HEMODYNAMICS OF PH
The main function of the right ventricle is to deliver
venous blood to the pulmonary vasculature for oxygen
exchange. The right ventricle is sensitive to increased after-
load, mainly determined by pulmonary vascular resistance.
Excessive and prolonged increase of afterload due to PH
impairs right ventricular ﬁlling and contractility [25]. Over
time, continued pressure overload cannot be sustained by
the right ventricle, which leads to decreased elasticity and
impaired contractility. Patients may experience repeated
acute right-sided heart decompensation and eventually
global cardiac dysfunction and death [26].
A mean pulmonary artery pressure of 8 to 20 mm Hg is
considered normal, and PH is deﬁned as a mean pulmonary
artery pressure >25 mm Hg at rest [27]. Elevation of
pulmonary artery pressure can be caused by primary PAH,
left-sided heart disease, lung disease, and thromboembolic
disease [28]. Table 2 reviews the various hemodynamic
deﬁnitions of PH that can assist in the diagnosis and under-
lying etiology.
CLASSIFICATION
In 2008, the 4th World Symposium of Pulmonary
Hypertension created consensus general guidelines and
a classiﬁcation of PH, dividing PH into 5 large subtypes
[29,30]: PAH, PH from left-sided heart disease, PH due to
lung disease, chronic thromboembolic PH, and PH with
unclear multifactorial mechanisms (Table 3). The reportedcases of PH after HSCT have been classiﬁed as PAH, PVOD,
and PVOD with pulmonary arterial involvement. In general,
PH after HSCT that is not a consequence of heart disease falls
into the ﬁrst category of this classiﬁcation. The underlying
diagnoses for which transplant is performed, for example,
myeloproliferative disorders, as well as potential complica-
tions from HSCT, such as heart disease and thromboembo-
lism, can give rise to PH of various classiﬁcations. In general,
PH occurring in older persons as a consequence of these
known etiologies is not reported in the HSCT literature,
weighting the literature toward younger persons with direct
vascular injury speciﬁc to HSCT, which is the major focus of
this review.
Pulmonary Arterial Hypertension
PAH is deﬁned by a progressive increase of pulmonary
arterial vascular resistance leading to right ventricular failure
and premature death. Histopathologically, PAH is character-
ized by vascular proliferation and remodeling of all 3 levels of
the vessel wall, with proliferative and obstructive changes
including endothelial, smooth muscle cells, and ﬁbroblasts
[31]. Pulmonary vasoconstriction is a signiﬁcant early
component in PAH. Early in the disease, PAH might be
asymptomatic or may present with very nonspeciﬁc symp-
toms such as exertional dyspnea and fatigue, making early
diagnosis in HSCT patients very challenging. If untreated,
PAH results in a progressive increase in mean pulmonary
artery pressure and pulmonary vascular resistance, leading
to right ventricular failure and death [32].
PAH evolves after a trigger, causing pulmonary arteriole
intimal damage later and resulting in hypertrophy through
smooth muscle proliferation and ﬁbroblast inﬁltration. The
trigger may also result from an increase in intravascular wall
stress and presumed intimal damage [33].
PAH has been reported in nearly all forms of inherited and
acquired hemolytic anemias as well as in patients with TA-
TMA [4,15,22,34]. In sickle cell and paroxysmal nocturnal
hemoglobinuria, the NO pathway is shown to be involved in
PH, as decreased synthesis or consumption of NOmay lead to
increased vasoconstriction [32,35]. PH has also been shown
to develop in patients with HSCT-associated-TMA. TA-TMA
occurs when endothelial injury, in the context of HSCT,
causes microangiopathic hemolytic anemia and platelet
consumption, resulting in thrombosis and ﬁbrin deposition
in the microcirculation and end-organ injury [36,37]. The
kidney is most commonly affected, but untreated TA-TMA
may evolve into multivisceral disease that also affects the
lungs, with associated PAH.
Pulmonary Veno-Occlusive Disease
PVOD is an uncommon entity, with an incidence of .1 to
.2 cases per million and was ﬁrst termed in 1966 as an
obstructive disease of the pulmonary veins [38]. PVOD affects
the pulmonary venules, with some reports mentioning
arteriolar involvement. In the general consensus guidelines,
PVOD is listed as a distinct category under PAH [29]. The
clinical presentation of PAH and PVOD are the same, and
genetic abnormalities in the bone morphogenetic protein
receptor type II (BMPR2) defect has been found in both types
of PH [39]. Simonneau et al. [40] proposed that both PVOD
and PAH may be a different aspect of the same disease and
noted that it is not possible to differentiate PVOD fromPAHby
clinical symptoms alone nor by cardiac catheterization. Ulti-
mately, the diagnosis of PVOD or PAH can only be made by
lung biopsy to determine the exact vascular compartment
Table 1
Reported Case Series (2 or more cases) of Patients Who Developed PH after HSCT
Reference Age at
Transplantation
Sex Diagnosis Conditioning
Regimen
HSCT
Type
PH
Classiﬁcation
Diagnosis of PH Symptoms Diagnosis Modality Treatment Outcome
Hackman
et al. [2]
4 yr F ALL MA MRD  2 PVOD, arterial
involvement
Day þ46 of
second SCT
Dyspnea Biopsy Methylprednisolone Died from relapsed
disease
4 yr M ALL MA MRD PVOD Day þ60 Dyspnea ECHO, Cath Methylprednisolone Alive at day þ230
Steward
et al. [11]
3.5 mo M MIO MA MRD PAH Day þ8 Tachypnea, hypoxia ECHO Deﬁbrotide Died of PH
1 mo M MIO MA MMRD PAH Day þ20 Tachypnea, hypoxia ECHO iNO, epoprostenol, nicardipine Died of PH
2 mo F MIO MA MRD PAH Day þ48 Tachypnea, hypoxia ECHO iNO, deﬁbrotide, epoprostenol Alive at 25 mo
1.5 mo F MIO MA MMRD PAH Day þ49 Tachypnea, hypoxia Cath iNO, surfactant, epoprostenol Died of PH
3 mo F MIO MA MUD PAH Day þ53 Tachypnea, hypoxia ECHO iNO, epoprostenol Alive at 31 mo
1 mo F MIO MA MMRD PAH Day þ65 Tachypnea, hypoxia ECHO iNO Died of PH
8 mo M MIO MA MMRD PAH Day þ60 Tachypnea, hypoxia ECHO, Cath Deﬁbrotide, epoprostenol Alive 3 mo later
8 mo M MIO MA MMRD PAH Day þ96 Tachypnea, hypoxia ECHO, autopsy iNO, deﬁbrotide,
methylprednisolone
Died of PH
Limsuwan
et al. [14]
15 yr M ALL MA MRD PAH 8 mo Dyspnea, hypoxia, syncope CT, ECHO, Cath, biopsy Iloprost, sildenaﬁl, beraprost Alive at 12 mo
16 yr F CML MA MUD PAH 4 mo Dyspnea, edema CT scan, CXR, ECHO, Cath Beraprost, sildenaﬁl Alive at 6 mo
Limsuwan
et al. [18]
19 yr M ALL MA NR PAH 8 mo Syncope, desaturations ECHO, Cath, biopsy Iloprost, sildenaﬁl, beraprost Alive at 48 mo
20 yr F CML MA MUD PAH 4 mo Dyspnea, edema CT, ECHO, Cath Sildenaﬁl, beraprost Alive at 30 mo
7 mo F HLH RIC MMUD PAH 9 mo Respiratory distress,
respiratory failure
CT, autopsy None Died, PH found on
autopsy
Zeilhofer
et al. [21]
4 mo F HLH RIC MMUD PAH 4 mo Respiratory distress, hypoxia ECHO, autopsy iNO Died of PH
1.8 yr M XLP RIC MMUD PAH Day þ169 Respiratory distress,
respiratory failure
ECHO, autopsy iNO Died of PH
Jodele
et al. [22]
5.8 yr F FA MA MUD PAH Day þ79 Hypoxia, respiratory failure ECHO, Cath iNO, atrial septostomy Died of PH
6 mo M HLH RIC MMUD PAH Day þ208 Hypoxia, respiratory failure ECHO, autopsy iNO Died of PH
1.8 yr M XLP RIC MRD PAH Day þ71 Hypoxia, respiratory failure Autopsy iNO Died of PH
10.4 yr F CML MA MUD PAH Day þ250 Hypoxia, respiratory failure ECHO, biopsy Sildenaﬁl Alive
3 mo M ATRT MA SAT PAH Day þ7 of
second SCT
Tachypnea, hypoxia ECHO, biopsy None Died of disease
progression
Schechter
et al. [23]
4 mo F ATRT MA SAT PAH Day þ5 of 3rd SCT Respiratory failure ECHO, biopsy iNO, steroids Died of PH
32 mo M Medulo MA SAT PAH Day 0 of 3rd SCT Hypoxia, respiratory distress ECHO, biopsy iNO Died of PH
ALL indicates acute lymphoblastic leukemia; ATRT, atypical teratoid rhabdoid tumor; Cath, cardiac catheterization; CML, chronic myeloid leukemia; CXR, chest x-ray; ECHO, echocardiography; HLH, hemophagocytic lym-
phohistiocytosis; MA, myeloablative regimen; Medulo, medulloblastoma; MIO, malignant infantile osteopetrosis; MMRD, mismatched related donor; MRD, matched related donor; MMUD, mismatched unrelated donor; MUD,
matched unrelated donor; NR, not reported; RIC, reduced-intensity conditioning; SAT, sequential autologous transplant; XLP, X-linked lymphoproliferative disorder.
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Table 2
Hemodynamic Deﬁnitions of PH
Deﬁnition Characteristics Clinical Groups of PH
Precapillary PH Mean pulmonary artery
pressure >25 mm Hg
and decreased capillary
wedge pressure
 PAH
 PH to lung disease
 Chronic
thromboembolic PH
 PH with unclear and
or multifactorial
mechanisms
Postcapillary PH Mean pulmonary artery
pressure >25 mm Hg
and increased capillary
wedge pressure
 Left-sided heart
disease PH
PH is deﬁned as a mean pulmonary artery pressure >25 mm Hg. PH
secondary to left-sided heart disease will have increased capillary wedge
pressures in comparison with all other clinical groups of PH. Adapted from
Bossone et al. [28].
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PVOD) is likely not key, because treatment is similar. One-
year mortality reported in the literature in patients with
PVOD is as high as 70% [41].
PH from Left-Sided Heart Disease
PH caused by left-sided heart disease may occur in some
patients, especially those with left-sided heart dysfunction
before transplantation [42]. Congestive heart failure may
develop from any or a combination of cardiotoxic medica-
tions, mitral or aortic stenosis, coronary artery disease, or
infectious myocarditis [29]. This type of PH occurs because of
an increase in left atrial pressure with pulmonary venous
congestion, which creates a passive increase in pulmonary
arterial pressure. It is important that patients with suspected
PH have a comprehensive cardiac assessment.
PH Due to Hypoxia and Interstitial Lung Disease
Patients undergoing HSCT are at risk of developing
interstitial pneumonitis, bronchiolitis obliterans, bronchio-
litis obliterans with organizing pneumonia, diffuse alveolar
damage, and lymphocytic interstitial pneumonia, among
others [43]. Development of PH has been associated with
bronchiolitis obliterans in lung transplant patients [44].Table 3
Updated Clinical Classiﬁcation of PH
Classiﬁcation
1. PAH
 Idiopathic PAH
 Heritable
 Drug and toxin induced
 Associated with chronic hemolytic anemia
 PVOD
2. PH due to left-sided heart disease
 Systolic dysfunction
 Diastolic dysfunction
 Valvular disease
3. PH due to lung diseases and/or hypoxia
 Chronic obstructive pulmonary disease
 Interstitial lung disease
 Pulmonary diseases with mixed restrictive and obstructive pattern
 Sleep-disordered breathing
 Alveolar hypoventilation disorders
4. Chronic thromboembolic PH
5. PH with unclear multifactorial mechanisms
 Hematological disorders: myeloproliferative disorders, splenectomy
 Systemic disorders: sarcoidosis, pulmonary Langerhans cell histiocytosis,
vasculitis
 Metabolic disorders: glycogen storage disease, Gaucher disease
Consensus general classiﬁcations taken from the 4th World Symposium of PulmonLong-term hypoxemia can lead to vascular remodeling and
angiogenesis, which in turn leads to increased vessel wall
proliferation and increased vascular resistance [45].PH Due to Miscellaneous Causes
Type 5 PH encompasses disorders with multifactorial
mechanisms, each of which alone are rare but signiﬁcant,
because these patients may present for HSCT and may have
PH before the transplantation starts. Patients with myelo-
proliferative disorders and those who have undergone
splenectomy have a higher incidence of PH, although
a mechanism for this has not been reported [46,47]. Patients
with systemic disorders such as Langerhans cell histiocytosis
and sarcoidosis are at high risk of developing PH secondary
to chronic inﬂammation and destruction of the vascular bed
[48,49]. Patients with underlyingmetabolic disorders such as
Gaucher disease are at risk of developing PH secondary to
glycolipid-laden macrophages inﬁltrating pulmonary capil-
laries and causing intimal ﬁbrosis [50].
Steward et al. [11] described PH in 29% of pediatric
patients (8 of 28) who underwent HSCT for malignant
infantile osteopetrosis. Their report identiﬁed 6 patients
(75%) who required assisted ventilation and 5 patients (62%)
who died from respiratory complications. The underlying
etiology of PH in patients with osteopetrosis is not known,
but PH should be strongly considered in the differential
diagnosis of respiratory distress in children with osteopet-
rosis after HSCT.PATHOLOGICAL FINDINGS IN PH AFTER HSCT
PH after HSCT has been described as affecting both
pulmonary arterioles and venules [6,13,22,51,52]. Histo-
pathological changes found in PAH affect all vascular layers of
arterioles, including proliferation of the smooth muscle cells,
intimal proliferation, medial hypertrophy, ﬁbrotic changes,
adventitial thickening, and perivascular inﬂammatory inﬁl-
trates (Figure 1A) [29,53,54]. Plexogenic lesions can form in
patients with chronic PAH (Figure 1B). In patients with TA-
TMA and PAH, the vascular lesions may show endothelial
injury and vascular wall hypertrophy of different age andEtiology
 Due to remodeling of pulmonary arteries and arterioles
 Increased pulmonary vascular resistance
 Increased pulmonary artery pressure due to left-sided heart disease
 No increase in pulmonary vascular resistance
 PH due to chronic lung disease
 PH due to thromboemboli
 Unclear etiology
ary Hypertension with brief description of etiology [29,30].
Figure 1. Lung pathology of pulmonary hypertension. (A) Lung pathology of pulmonary arterial hypertension. Severe muscle proliferation (a) and intimal prolif-
eration (b), with almost complete obliteration of the vessel lumen (c) in a patient with severe PH. The internal (d) and external elastic lamina (e) are still present. (B)
Plexogenic pulmonary arteriopathy. Complicated plexogenic lesions in a completely obliterated vessel in a patient with severe PH. Multiple tortuous vessels are seen
in the previous vessel lumen (arrows). (C and D) PVOD; patchy thickening of alveolar septa and intimal ﬁbrosis narrowing the pulmonary veins (arrows). (Reprinted
from Miura et al. [55] with permission from Elsevier). A, B, and C are H & Eestained images at 40. D is an elastica-van Giesonestained image at 40.
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hemorrhages.
Histologically, PVOD is characterized by extensive occlu-
sion of the pulmonary venuleswith ﬁbrous tissue that evolves
into sclerotic occlusion without thrombosis (Figure 1C).
Anti-a-actin staining may show involvement of the smooth
muscle cells as well as myoﬁbroblasts within the venules
[39,54,55].
DIAGNOSIS OF PH
Medical and Family History
Early identiﬁcation and diagnosis of PH is critical so that
timely treatment may be initiated before right-sided heart
failure and irreversible cardiac compromise. In HSCT
patients, family history might be unrevealing because most
risk factors are associated with HSCT therapy or complication
in these patients. Questions should be directed to identify
relatives with PH or early cardiac disease and detailed
thrombophilia history to identify events of deep vein
thrombosis or pulmonary emboli.
Differential Diagnosis of Respiratory Symptoms after
Transplantation
The most common pulmonary complications after trans-
plantation include infectious pneumonia, acute respiratory
distress syndrome, pulmonary edema, diffuse alveolar
hemorrhage, heart failure, interstitial pneumonitis, idiopathic
pneumonia syndrome, bronchiolitis obliterans, and orga-
nizing pneumonia [24,56]. PH is rarely included in the differ-
ential diagnosis of respiratory distress post-transplantation
and can be easily overlooked. The most common respiratory
symptoms reported in patients with PH in the literature are
acute hypoxemia (72%), dyspnea (33%), and acute respiratory
failure (37%) with no clear underlying cause [3-25]. It is not
uncommon that hypoxemia and acute respiratory failureoccur after additional stressors such as anesthesia or a septic
event, likely inducing acute collapse of already injured
pulmonary vessels [3]. It is important to consider PH
among other common diagnoses after HSCT in patients with
unexplained hypoxemia or respiratory distress, especially in
those requiring intensive care, so appropriate diagnostic
studies can be initiated [57].
Clinical Symptoms of PH
The initial symptoms of PH, including shortness of breath,
fatigue, dizziness, weakness, and hypoxemia, can be vague
and difﬁcult to differentiate in the post-transplantation
patient. Edema and ascites may develop in later stages
from increased venous congestion [29,58]. Patients with
advanced disease develop progressive tachypnea and
hypoxemia preceding respiratory failure. Unrecognized and
untreated PH in HSCT patients is nearly always lethal.
Findings on Physical Examination
Initial ﬁndings on physical examination in patients with
PH may be subtle. However, with more advanced PH, phys-
ical signs become more obvious. Peripheral signs of elevated
central venous pressure such as jugular venous distension
are well recognized in adult clinical practice but may be
overlooked in children. Peripheral, ﬂank, or periorbital
edema may be present [32]. Hepatomegaly or ascites are
further indications of elevated central venous pressure but
may be difﬁcult to differentiate from other causes in patients
after HSCT. A parasternal lift and palpable second heart
sound component in the second left intercostal space are
surface manifestations of an exaggerated second heart
sound. These are borne out on auscultation when an exag-
gerated pulmonic component of the second heart soundmay
be heard. A holosystolic murmur may be audible in the
tricuspid area if tricuspid regurgitation is present, and an
Table 4
Echocardiographic Guidelines for the Diagnosis of PH
Echocardiographic Evaluation Likelihood of PH
TRV <2.8 m/s and SPAP <36 mm Hg with
no secondary characteristics of PH
Unlikely
TRV of 2.9-3.4 m/s and SPAP of 37-50 mm Hg
or secondary characteristics of PH
Possible
TRV >3.4 m/s and SPAP >50 mm Hg with or
without secondary signs of PH
Likely
Echocardiograph evaluation of the tricuspid regurgitant velocity (TRV) is
needed to calculate the systolic pulmonary artery pressure (SPAP). These
values help determine the likelihood of a diagnosis of PH. Guidelines
adopted from the European Society of Cardiology Guidelines [29,30].
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representative of pulmonary insufﬁciency, is also occasion-
ally heard. In the face of deteriorating ventricular function,
third and fourth sound gallops may also become evident
[58]. These ﬁndings are representative of both failing systolic
function and deteriorating ventricular compliance, when
more active atrial contraction becomes necessary to ﬁll the
right ventricle and maintain adequate output.
Chest Radiography
Up to 90% of patients with advanced PH have abnormal
ﬁndings on chest x-ray. These ﬁndings can include promi-
nence of the pulmonary artery, enlarged hilar vessels, and
decreased peripheral vessels. In the early stages of PH,
radiological studies may not show any lung abnormalities
and vascular changes might be difﬁcult to appreciate [22]. PH
should be considered in the differential diagnosis of any
HSCT patient with “unexplained” hypoxemia or respiratory
distress without obvious radiological lung abnormalities or
documented infections [58].
Electrocardiography
Electrocardiograms of patients with PH may show
evidence of right atrial enlargement or right ventricular
hypertrophy with peaked P waves, right axis deviation,
excessive electrical forces in the anterior leads, and right
bundle branch block pattern. Electrocardiography is sensitive
as a tool for diagnosing right ventricular hypertrophy but is
not sufﬁciently speciﬁc as a screening tool to rule out PH [59].
High-Resolution Chest Computed Tomography and
Magnetic Resonance Imaging
Computed tomography (CT) is a useful modality in iden-
tifying patients with PH, and high-resolution CT scanners
allow for improved resolution, shorter scanning times, and
shorter breath holds. Dilation of the pulmonary artery is an
important ﬁnding in patients with PH and, when detected on
CT scan, has a 77.4% sensitivity and 89.6% speciﬁcity of
detecting PH [60]. High-resolution CT is helpful in identifying
patients with pulmonary PVOD and can show interstitial
lung edema, diffuse ground-glass opacities with a cen-
trilobular distribution, adenopathy, and septal lines [61]. CT
scans can give insight to underlying etiologies of PH such as
pulmonary emboli.
Cardiac magnetic resonance imaging (MRI) is the gold
standard for functional and structural assessment of right-
sided cardiopulmonary circulation [60]. Cardiac MRI can
provide an excellent anatomical and functional evaluation
without radiation exposure, and it enables the radiologist to
evaluate for right atrial dilation, right ventricle hypertrophy,
and septal ﬂattening [62]. Finally, MRI can provide informa-
tion on right ventricular global dysfunction [26]. CT and MRI
may not be options for critically ill HSCT patients and are not
suitable for longitudinal monitoring and will likely only
identify symptoms of advanced disease.
Echocardiography
Transthoracic echocardiography is an excellent noninva-
sive screening tool for PH [29,63]. Dedicated echocardiog-
raphy speciﬁcally targeting signs of PH should be requested
and should be interpreted by a cardiologist or PH specialist. It
is important to note that in most institutions, routine echo-
cardiography requested to evaluate cardiac function will not
include a comprehensive right-sided heart evaluation and
will not be sufﬁcient to rule out PH. For this reason, speciﬁcechocardiographic protocols have been developed for this
purpose. An example of such an echocardiographic protocol
for evaluation of PH is shown in Appendix 1.
Using echocardiography, right ventricular pressure can be
estimated with interrogation of the Doppler regurgitant jet
velocity across the tricuspid valve if tricuspid regurgitation is
present. In the absence of tricuspid regurgitation, dedicated
echocardiography to speciﬁcally evaluate PH may reveal
subtle ﬁndings otherwise overlooked. These less direct signs
of PH may include evidence of right-sided heart chamber
dilation, right ventricular hypertrophy, systolic septal ﬂat-
tening, or dilated pulmonary arteries. These signs may not
always be found in patients with mild PH, and some of these
may be late ﬁndings [22]. Given these limitations in
screening patients with mild or early PH, the HSCT physician
should be aware that echocardiography might need to be
repeated over time.
Echocardiography is also an excellent noninvasive means
to assess the response to treatment if signiﬁcant PH is found
on the initial screening study and therapy was initiated. The
intervals at which echocardiography should be repeated
depend on the severity of the diagnosed PH, extent of
treatment, and the clinical setting. Echocardiographic
guidelines for diagnosis of PH are listed in Table 4.
Cardiac Catheterization
Cardiac catheterization remains the gold standard in the
diagnosis of PH and should be considered in the HSCT patient
suspected of PH after proper risk and beneﬁt assessment.
During cardiac catheterization, cardiac output is directly
measured, the impact of intracardiac shunts is evaluated,
pulmonary artery pressures are measured, and pulmonary
resistance can be calculated [30]. If signiﬁcant PH or eleva-
tion of pulmonary resistance is present, it is recommended
that all patients undergo acute vasodilator testing. Currently,
iNO, intravenous epoprostenol, or adenosine are recom-
mended, with iNO the drug of choice for acute vasodilator
testing [64,65]. The information derived from vasodilator
testing is essential for the best PH therapy selection.
In general, given the potential risks of cardiac catheteri-
zation in a population with other signiﬁcant comorbidities,
such as those after HSCT, invasive testing is reserved for
those in whom a clear diagnosis cannot be achieved with
noninvasive means. In addition, any patient with apparent
hemodynamically compromising PH (at any stage of treat-
ment) should undergo cardiac catheterization, as well as
those who do not appear to be responding appropriately to
ﬁrst-line PH therapy (see Treatment of PH, below).
BIOMARKERS
Novel biomarkers for PH diagnosis and monitoring after
HSCT would be valuable but are not currently available.
Table 5
Biomarkers of PH
Biomarker* Relevance
Human pentraxin 3 (PTX3) Acute-phase reactant, a speciﬁc biomarker for PH reﬂecting pulmonary vascular degeneration
N-terminal of brain natriuretic peptide (NT-ProBNP) An inactive amino-terminal fragment of brain natriuretic peptide predicts long-term outcome
in severe PH; highly speciﬁc/sensitive in PH
Endothelin-1 (ET-1) Vasoconstrictor, involved in vascular remodeling; increased in PH; bosentan is an ET-1 receptor
antagonist and a potential target for therapy
Angiopoietin-2 (Ang-2) Angiogenic factor essential for vascular development and maturation; correlates with disease
severity in PH
Bone morphogenic protein-9 (BMP-9) Circulating peptide; affects endothelial function and associated with ET-1 in PH
Endoglin (Eng) Membrane glycoprotein involved in vascular remodeling; increased in patients with PH in
systemic sclerosis
Vascular endothelial growth factor (VEGF) Signal protein involved in vasculogenesis; potent mediator of vascular regulation in
angiogenesis; increased in PH
Transforming growth factor b (active TGF-b) Multifunctional peptide secreted by cells that control epithelial cell differentiation, proliferation,
and function; found downstream of therapeutic agent losartan
Soluble vascular cell adhesion molecule-1 (sVCAM-1) Endothelial adhesion molecule that correlates with PH in sickle cell disease; normally suppressed
by NO; potential treatment with ET-1 receptor antagonist bosentan
Asymmetrical dimethylarginine (ADMA) NO synthase inhibitor; increased in PH in sickle cell disease and contributes to decreased
NO production
* Biomarkers used in PH for diagnostic, prognostic, or therapeutic purposes.
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settings and are listed in Table 5.TREATMENT OF PH
PH therapy can be disease speciﬁc or supportive. Ideally,
a cardiologist or PH specialist should prescribe targeted PH
therapy after thorough patient evaluation. Figure 2 shows
a suggested treatment algorithm for PH after HSCT [29,32].Supportive Therapy
The initial focus of therapy should be aimed at optimizing
cardiac function, especially if PH has resulted in right ven-
tricular compromise. Pharmacological agents useful for this
purpose are described.
Diuretics
Right-sided heart failure can lead to ﬂuid retention with
resulting hepatic congestion, pulmonary edema, ascites, andFigure 2. Treatment algorithm for PH unresponsive to ﬁrst-line therapy of hemody
terase-5; ERA, endothelin receptor antagonist. (Algorithm adopted from [29,32].)peripheral edema. Diuretics may be indicated to prevent
worsening ﬂuid retention, including hepatic congestion.
Excessive rapid diuresis may lead to decreased cardiac
output, however, so caution is required [29].
Afterload-reducing agents
Afterload-reducing agents reduce systemic vascular
resistance, improving cardiacmechanics. Although afterload-
reducing agents do not work speciﬁcally on the pulmonary
vasculature, they play an important role in improving left
ventricular efﬁciency when right ventricular hypertension
adversely affects the left ventricular morphology.
Intravenous inotropes
Bipyridine inotropes (eg, milrinone) selectively inhibit the
cyclic adenosine monophosphate phosphodiesterase isoen-
zyme found in both cardiac and vascular smooth muscle.
Inhibition leads to increased intracellular ionized calcium in
heart muscle cells, increased contractility, and peripheralnamically compromising PH, reﬂecting clinical practice. PDE-5, phosphodies-
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face of hemodynamically compromising PH [29].
Pulmonary Vasodilator Therapy
Various drugs with differing mechanisms of action are
now available that speciﬁcally target the pulmonary vascu-
lature. Although often used in combination, adverse event
proﬁles and the means of administration should be taken
into account before commencing these therapies. Therapy is
frequently commenced on the basis of clinical diagnosis and
echocardiographic ﬁndings. Any patient with an estimated
right ventricular pressure greater than 50% of systemic
pressure should be started on treatment, even in the absence
of invasive testing (cardiac catheterization). Typical ﬁrst-line
therapies are supplemental oxygen (if evidence of hypoxia)
and phosphodiesterase-5 inhibitors. Nonresponse to initial
therapy or evidence of deterioration of PH with serial follow-
up screening is an indication for cardiac catheterization and
therapeutic testing, before escalation to other treatment
options (Figure 2).
Oxygen therapy
Oxygen is a potent pulmonary vasodilator and is used in
most patients with PH. In patients with PH but without
hypoxemia, oxygen therapy has been shown to improve
pulmonary vasodilation and perfusion [66]. In PH associated
with hypoxemia, oxygen therapy should be administered to
maintain oxygen saturations >90%. It is vitally important
that HSCT patients diagnosed with PH have immediate
access to supplemental oxygen. This is particularly relevant
in patients with PH in outpatient settings where symptoms
may be exacerbated by viral illness or other stressors.
Inhaled nitric oxide
NO is an endogenous vasodilator produced from L-argi-
nine, oxygen, and NADPH by various NO synthase enzymes. It
is used as a signalingmolecule in vascular endothelial cells to
signal triggering smooth muscle cells relaxation. Inadequate
or defective production of endogenous NO is a key mecha-
nism in the development of PH. NO can be administered as
a continuous inhalation (iNO) through a facemask, nasal
cannula, or endotracheal tube in intubated patients. NO
diffuses rapidly throughout the pulmonary vasculature,
decreasing vascular tone and relaxing pulmonary arteries.
Excess iNO is rapidly converted to nitrate and methemo-
globin after binding to hemoglobin and therefore causes few
systemic side effects [67]. iNO is often used in intensive care
settings for acute management of PH due to the ease of
administration and the favorable side-effect proﬁle.
Calcium channel blockers
Only a small number of patients with PH (those who
respond to pulmonary vasodilator testing) beneﬁt from
calcium channel blocker therapy. The most commonly used
calcium channel blockers in this setting are amlodipine,
nifedipine, and diltiazem. These agents are used less
frequently because of the availability of an increasing array of
newer pulmonary vasodilator drugs. Calcium channel
blockers are negative inotropic agents, often precluding their
use in the face of compromised hemodynamics [68].
Phosphodiesterase-5 inhibitors
Phosphodiesterase-5 inhibitors increase the effects of NO
by inhibiting breakdown. Increased NO results in vasodila-
tion and decreased smooth muscle proliferation. Sildenaﬁl,tadalaﬁl, and other phosphodiesterase inhibitors have been
shown to improve symptoms and length of distance during
6-minute walk tests as well as hemodynamic parameters
[69]. These drugs are generally administered orally, with
some available as intravenous formulations. The side-effect
proﬁle of these drugs is generally benign (headaches, hypo-
tension, and priapism), but the US Food and Drug Adminis-
tration has recently limited the use of sildenaﬁl in patients
with heritable or idiopathic PHdue to an increase inmortality
when used at higher doses in those speciﬁc populations.
Endothelin receptor antagonists
Endothelin is a potent vasoconstrictor implicated in the
pathogenesis of PAH. Endothelin has been found to cause
pulmonary arteriole smooth muscle vasoconstriction and
proliferation, ﬁbroblast proliferation, and endothelium pro-
liferation. Nonselective endothelin receptor antagonists (eg,
bosentan and ambrisentan) have become a part of the stan-
dard of care in patientswith chronic PAH [70]. These drugs are
administeredorally andhave a side-effect proﬁle that includes
hepatotoxicity, idiosyncratic anemia, and peripheral edema.
Monthly liver enzyme and complete blood counts are man-
datory for any patients treated with these drugs.
Prostanoids
Patients with PAH have reduced prostacyclin synthase,
resulting in decreased production of prostacyclin I2, a potent
vasodilator. Prostanoids, such as epoprostenol and trepros-
tinil, are potent vasodilators, acting directly on pulmonary
and systemic vascular beds to cause vasodilation [71]. They
have been shown to improve functional class and exercise
tolerance as well as survival in PAH [72,73]. These drugs do
have signiﬁcant side effects, including nausea and vomiting
with initial commencement in a dose-dependent manner,
diarrhea, jaw pain, and headache. Many different modes of
administration have been developed, although the most
common means of delivery when used chronically is by
continuous intravenous infusion through tunneled central
lines. Treprostinil is stable at room temperature (compared
with epoprostenol, which requires continuous cooling) and
has a substantially longer half-life. Treprostinil can be
administered subcutaneously, and an inhaled form is now
available in the United States. Orally administered prosta-
noids are not yet available in the United States.
Other Therapies for PH
Oral anticoagulation
Patients with PH secondary to thromboembolic disease
and thosewith extensive late disease from any etiology are at
risk of developing worsening disease from intrapulmonary
microthrombi [65]. Oral anticoagulation with a target Inter-
national Normalized Ratio of 2.0 is generally recommended
[29]. The risk-to-beneﬁt ratio of anticoagulation in patients
with PH after HSCT should be carefully weighed because of
the high risk of bleeding complications.
Atrial septostomy
Invasive therapeutic measures might be required in HSCT
patients with acute right-sided heart failure attributed to PH.
Under these circumstances, right ventricular output is dimin-
ished, resulting in decreased left atrial return, impaired left
ventricular preload, and a low cardiac output state. An atrial
septostomy allows right to left shunting at the atrial level and
provides adequate left atrialﬁlling. Cardiac output is enhanced
at the expense of lower systemic arterial saturations. The
Figure 3. Proposed algorithm for evaluation of possible PH after HSCT. (Algorithm adopted from Jodele et al. [22].)
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hemoglobin oxygenation due to the shunt, and tissue oxygen
delivery is typically enhanced [29].CONCLUSIONS
The lack of prospective studies evaluating PH after HSCT
limits insight into the etiology, incidence, and risk factors for
PH. PH should be considered in any HSCT patient with
hypoxemia, respiratory failure, or symptoms of TMA, intra-
vascular hemolysis, or thrombosis, especially those who are
critically ill (Figure 3). Recognition of PH in this population
requires a high degree of awareness followed by targeted
evaluation and clinical intervention, guided by an experi-
enced cardiologist. Noninvasive diagnostic methods such as
echocardiography are readily available and should be used
for PH evaluation, recognizing that early signs of PHmight be
missed, requiring diagnostic follow-up if respiratory or
cardiac symptoms persist. HSCT physicians should seek
prompt consultation with an experienced cardiologist when
PH is suspected. It is also important to properly communicate
the PH diagnosis to the anesthesia team in any HSCT patient
scheduled for procedures requiring sedatives because PH
may be exacerbated by such interventions, placing patients
at risk for acute respiratory decompensation.
Our incomplete understanding of the etiology of PH in
HSCT patients limits targeted noninvasive diagnostic and
therapeutic options, especially in children undergoing
transplantation. Children and young persons with PH post-
HSCT likely have a different mechanism of disease from
older persons with typical PH associated with long-standing
heart disease or multiple emboli. Reports of an association
with TA-TMA support the hypothesis that PH post-HSCT is
due to endothelial injury as a consequence of complement
activation [37]. Careful prospective studies, including state-
of-the-art diagnostics and biomarker studies, will help
elucidate mechanisms of disease and optimal therapy.ACKNOWLEDGMENTS
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